Maze Therapeutics (MAZE) Form 4: 18,000-share option to director

Rhea-AI Filing Summary

Maze Therapeutics director Richard H. Scheller was granted a stock option for 18,000 shares on 09/22/2025 at an exercise price of $23.67 per share. The option is exercisable under an agreement that vests in nine equal monthly tranches (1/9 monthly) with the first tranche scheduled to vest on October 1, 2025, subject to continued service. The option has an expiration date shown as 09/21/2035. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 09/24/2025.

Positive

• Director received an 18,000-share stock option grant, aligning his interests with shareholders
• Exercise price fixed at $23.67, establishing clear terms for potential future equity participation
• Monthly vesting (1/9) beginning Oct 1, 2025 supports retention over the near term

Negative

• None.

Insights

Financial Analyst

TL;DR: Director received an 18,000-share option grant at $23.67 with a multi-month vesting schedule; impact is routine and likely modest.

The grant aligns the director's incentives with shareholder value by tying compensation to future share performance. The five-year-plus contractual life to the stated expiration (through 09/21/2035) and monthly vesting beginning October 1, 2025, indicate a retention-oriented structure. No cash proceeds, accelerated vesting, or related-party purchase price anomalies are disclosed. For investors, this is a standard executive/director equity award rather than a material corporate event.

Corporate Governance Expert

TL;DR: Governance action appears routine: a time-based option grant to a director with standard service-based vesting and no unusual terms disclosed.

The Form 4 documents a straightforward equity grant to a director, reported timely. Vesting in nine monthly tranches beginning after appointment or grant date is somewhat front-loaded compared with typical annual cliffs, suggesting an intent to retain near-term service. There is no indication of new beneficial ownership thresholds or change in control protections disclosed. Filing completeness and signature by attorney-in-fact meet procedural requirements.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

SCHELLER RICHARD H

(Last) (First) (Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$23.67	09/22/2025		A		18,000		(1)	09/21/2035	Common Stock	18,000	$0	18,000	D

Explanation of Responses:

1. The option shall vest as to 1/9 of the total award monthly with the first tranche vesting on October 1, 2025, subject to the reporting person's continued service to the Issuer on the applicable vesting date.

	/s/ Courtney Phillips, as attorney-in-fact	09/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Richard H. Scheller report on Form 4 for MAZE?

He reported a grant of a stock option for 18,000 shares on 09/22/2025 at an exercise price of $23.67.

When does the option start vesting and how is it scheduled?

The option vests 1/9 of the total award monthly with the first tranche vesting on October 1, 2025, subject to continued service.

What is the expiration date of the option disclosed on the Form 4?

The expiration date shown on the form is 09/21/2035 for the underlying option award.

Was the Form 4 filed timely and who signed it?

The filing lists the transaction date as 09/22/2025 and was signed by an attorney-in-fact on 09/24/2025.

Does the Form 4 indicate any cash purchase or sale related to this transaction?

No cash purchase or sale is reported; the Form 4 records an option grant (derivative award) rather than a direct stock purchase.